Assessment of Corneal Biomechanical Properties Using Corvis ST Following LASIK, PRK, and CXL
Launched by BENI-SUEF UNIVERSITY · Feb 5, 2025
Trial Information
Current as of July 06, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain eye surgeries, specifically LASIK, PRK, and corneal cross-linking (CXL), affect the strength and flexibility of the cornea, which is the clear front part of the eye. Researchers are using a special device called the Corvis ST to measure these changes in patients who have had one of these procedures at least a month earlier. The goal is to understand better how these surgeries impact the cornea, especially for individuals with conditions like myopia (nearsightedness) or keratoconus (a condition that affects the shape of the cornea).
To be eligible for this study, participants need to be adults aged 18 to 60 who have had LASIK, PRK, or CXL and have stable vision for at least three months after their surgery. They should not have other eye diseases or infections. If you choose to participate, you can expect a thorough assessment of your corneal health using the Corvis ST. It's essential to note that individuals with certain other eye conditions or those who have taken specific medications may not qualify for this trial. Overall, this research aims to improve our understanding of how different eye surgeries impact corneal health, which can help inform future treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - 1. Adults aged 18-60 years. 2. Patients who have undergone LASIK, PRK, or CXL at least 1 month prior to measure-ment.
- • 3. Stable refraction for at least 3 months post-procedure. 4. No evidence of active ocular disease or infection.
- Exclusion Criteria:
- • 1. History of other ocular surgeries (excluding LASIK, PRK, or CXL). 2. Presence of keratoconus or other corneal ectatic disorders not treated with CXL.
- • 3. Systemic or ocular conditions affecting corneal biomechanical properties (e.g., dia-betes, connective tissue disorders).
- • 4. Current or recent use of medications influencing corneal biomechanics.
About Beni Suef University
Beni-Suef University is a prominent academic institution in Egypt dedicated to advancing medical research and clinical trials aimed at improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university fosters a multidisciplinary approach to research, engaging faculty, students, and healthcare professionals in the pursuit of scientific knowledge. The institution is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring that all clinical trials conducted under its auspices are designed to enhance patient care and contribute to the global body of medical research. Through its initiatives, Beni-Suef University aims to translate research findings into practical applications that benefit communities locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mohandessin, Giza, Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported